Front-Line Therapy with Brentuximab Vedotin Combined with ABVD or AVD for Advanced HL


Front-Line Therapy with Brentuximab Vedotin Combined with ABVD or AVD for Advanced HL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)

Ansell SM et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Proc ASH 2012;Abstract 798.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.